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Summary The possibility that medroxypregesterone acetate (MPA) is clinically effective at least in part by its
suppression of adrenal steroidogenesis and a resultant reduction of circulating oestrogen levels was
investigated in 49 postmenopausal patients with advanced breast cancer. Thirty-one patients were treated with
low dose MPA (100mg three times daily) and 16 patients with high dose MPA (250mg four times daily).
Plasma levels of androstenedione, testosterone, oestrone and oestradiol were all significantly reduced during
treatment, with the suppression being most marked for the 17fl hydroxysteroids, testosterone and oestradiol.
The fall in oestradiol levels was to about 50% of pretreatment levels, but a concomitant fall in SHBG levels
to less than 25% of baseline probably resulted in the fall in free, biologically active oestradiol being only to
about 70-80% of pretreatment. It is unlikely that this is a major determinant of the activity of MPA in breast
cancer.
Clinical interest in the use of medroxyprogesterone acetate
(MPA) in advanced breast cancer has been stimulated by the
observation that high doses of MPA may be more effective
than conventional lower doses (Pannuti et al., 1978). The
mechanism of action of MPA is unclear (Stoll, 1981) but a
number of suggestions have been made. One possibility is
that MPA may act by increasing the oxidative activity of 17,B
hydroxysteroid dehydrogenase, thereby increasing the
conversion of oestradiol to oestrone, an oestrogen of lower
potency (Tseng & Gurpide, 1975). Progestogens also have an
additional 'anti-oestrogenic' activity due to their suppression
of oestrogen receptor levels (Clark & Peck, 1979).
A further effect of MPA which may be important in
postmenopausal patients is the drug's suppressive effect on
adrenal steroidogenesis (van Veelen et al., 1985a, b) since
after the menopause adrenal androgens are major precursors
of plasma oestrogens (Grodin et al., 1973). In this study we
have measured the MPA-induced changes in the levels of the
major adrenal androgens, as well as those of oestradiol and
oestrone in postmenopausal breast cancer patients treated
with both high- and low-dose MPA. In addition, the levels
of sex hormone binding globulin were measured since this
may affect both the circulating levels and biological activities
of testosterone and oestradiol (Siiteri et al., 1982).
Patients and methods
Forty-nine postmenopausal patients (last menopausal period
at least 2 years previously) with histologically proven
advanced metastatic breast cancer were treated orally with
MPA either 100mg three times daily (low dose) or 250mg
four times daily (high dose). The patients were part of a
larger clinical trial of these treatments and were assigned
randomly to the dose received. By chance 33 patients
received the low dose and 16 received the high dose. Twenty-
one patients (12 low, 9 high dose) were either previously
untreated or had not received endocrine treatment for at
least one month. Twenty patients (15 low, 5 high dose)
transferred directly from tamoxifen treatment to MPA and 8
patients (6 low, 2 high dose) transferred directly from
treatment with aminoglutethimide.
Blood samples were taken from patients prior to treatment
and at intervals (in most cases, monthly) during treatment at
outpatient clinic. The samples were taken at the same time
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of day for each patient. Serum was stored at -20°C until
analysis.
Androstenedione (Dowsett et al., 1984a), testosterone (Sufi
et al., 1986), oestradiol and oestrone (Harris et al., 1983) and
dehydroepiandrosterone sulphate (Harris et al., 1982) were
measured by radioimmunoassay according to previously
published methods. SHBG binding capacity was measured
by the two-tier column method (Dowsett et al., 1985a). No
significant cross-reaction was found with levels of MPA up
to 1 HIgml-1 in any of the assays.
Statistical comparisons were made using paired and
unpaired t-tests. In cases where multiple comparisons were
made using the same data, appropriate correction of
probability values was made using the Bonferroni inequality
(Miller, 1966).
Results
Samples from the 20 patients who had received tamoxifen
until immediately before MPA treatment were excluded from
the SHBG analysis and those from the 8 patients receiving
aminoglutethimide were only analysed for SHBG because of
the known effects of tamoxifen on SHBG (Sakai et al., 1978)
and of AG on all five steroids (Stuart-Harris et al., 1985).
Statistical comparisons were performed which confirmed that
there were no significant differences in the mean
pretreatment levels of the remaining analytes between the
treated and untreated patient groups. The data from these
groups were therefore pooled.
The hormone levels before and during treatment are
shown in the Table. Results have been pooled within two
periods during treatment (1-2 months and >3 months) and
where two results were available for a patient within one of
the time periods the mean value was taken for statistical
purposes.
Testosterone levels were significantly reduced at both time
points for both dose groups but there was no significant
reduction in androstenedione levels in any of these individual
groups. However, when the data from both dose groups
were pooled the mean level of androstenedione after at least
3 months' treatment was significantly lower than pre-
treatment levels (P=0.01). Fewer values were available for
DHAS but there were significant falls at both doses after 1-2
months' treatment. Additionally, the levels for both DHAS
(P<0.05) and testosterone (P<0.01) during that period were
significantly lower in the higher dose group.
The mean level of oestrone was lower on-treatment at
The Macmillan Press Ltd., 1987 Br. J. Cancer (1987), 55, 311-313312 M. DOWSETT et al.
Table I Hormone levels in postmenopausal breast cancer patients before and after 1-2 months and
>3 months on-treatment with 3 x O00mg (low dose) or 4 x 250mg (high dose) MPA oral daily. The
figures in parentheses indicate the number in each group
Low dose High dose
Hormone Pre 1-2m >3m Pre 1-2m >3m
Androstenedione 2.1 +0.3 1.8+0.2 1.6+0.3 1.7+0.4 1.5+0.4 1.0+0.2
nmoll- 1 (22) (26) (8) (13) (14) (8)
Testosterone 1.10+0.10 0.70+0.14b 0.75+0.15b 1.02+0.17 0.40+O.O9b 0.52+0.14a
nmoll-1 (21) (24) (14) (11) (13) (8)
DHAS 2.9+0.7 1.9+0.5a 1.4+0.6 2.1+0.8 0.3+0.la 0.3+0.1
jumol l-I' (1) (I l) (3) (7) (7) (5)
Oestrone 125+11 114+11 102+11 127+18 98+11 102+18
pmoll-1 (22) (26) (16) (13) (14) (8)
Oestradiol 45.3 +6.5 28.5+4.9b 27.7+6.Oa 30.4+6.0 20.3+3.1 14.6+2.8a
pmoll- 1 (24) (27) (16) (13) (14) (8)
SHBG 65.9 +7.5 20.4+2.8b 14.2+2.7b 60.0+ 8.6 17.7+4.5b 8.9+2.3b
nmoll-1 (17) (18) (11) (9) (11) (7)
ap<0.05; bp<o.Ol versus mean pretreatment level.
both time points, for both dose groups but these differences
lacked statistical significance. The level was found to be
significantly lower (P<0.05) after 1-2 months when the data
from both dose groups were pooled. The mean pretreatment
value for oestradiol was considerably lower, albeit not
statistically significantly so (P=0.14) for the higher dose
group. There was significant suppression of oestradiol levels
at both time points for the low dose group but only after 3
months' treatment for the higher dose group.
In both dose groups there was a marked fall in SHBG
binding capacity after 1-2 months' treatment. After pooling
of the data from both dose groups a further significant fall
was found during treatment (P<0.05).
Discussion
The high response rate (43%) reported by Pannuti et al.
(1978) to high dose MPA (ISOOmgi.m. daily) has led to
increased interest in the use of this drug in advanced breast
cancer. The mechanism of action remains obscure, however,
and it is not clear whether high dose therapy acts by a
mechanism which is additional to that by which lower doses
are effective. It has been suggested that in postmenopausal
women MPA may exert at least part of its activity by
suppression of adrenal androgen synthesis and the
consequent reduction in circulating oestrogens which are
derived from the peripheral conversion of these androgens
(van Veelen et al., 1985a, b). The further suggestion has been
made that this inhibition of adrenal steroidogenesis may
explain the higher response rate found during the use of high
dose progestins (van Veelen et al., 1985a).
In the present study, SHBG and all of the five steroids
measured were suppressed to a variable extent by MPA
treatment and there were indications of a dose response in
the suppression of DHAS and testosterone. Similar effects
on DHAS, androstenedione and oestrone have been
demonstrated by van Veelen et al. (1985b). The degree of
suppression of all three hormones was greater in that report,
but this difference may be explained by the on-treatment
values being compared with an untreated control group in
that study rather than with the pretreatment values of the
same patients.
The suppression of the 17f hydroxysteroids - testosterone
and oestradiol - was greater than that of their 17 oxosteroid
counterparts - androstenedione and oestrone. This is despite
the latter pair of hormones having a greater dependence on
adrenal steroidogenesis in the postmenopausal female (Jaffe,
1986). The difference in the degree of suppression may be
related to the marked MPA-induced fall in SHBG binding
capacity in these patients, since androstenedione and
oestrone are bound only weakly by SHBG whereas
testosterone and oestradiol are both bound with high affinity
and falls in SHBG level are associated with increased
metabolic clearance rates of testosterone (Vermeulen et al.,
1969). We have previously demonstrated that testosterone
levels fall in association with danazol-induced suppression of
SHBG levels (Forbes et al., 1986). It is also possible that the
differential suppression of the 17,B hydroxy- and 17 oxo-
steroids may be due to an MPA-induced increase in the
oxidase activity of 17,B hydroxysteroid dehydrogenase (Tseng
& Gurpide, 1975).
It has previously been shown that MPA even in low doses
(150mg every 12 weeks in the depot form) can cause a
reduction in SHBG levels (Jeppsson et al., 1982) and that
levels are also reduced in breast cancer patients treated with
another progestogen, megestrol acetate (Alexieva-Figusch et
al., 1984) but this is the first report of SHBG changes in
association with androgen and oestrogen measurements in
postmenopausal breast cancer patients on MPA treatment.
The fall in SHBG levels is a reflection of the intrinsic
androgenicity of synthetic progestogens. The importance of
the fall to the interpretation of the changes in sex steroid
levels lies not only in its effects on metabolic clearance rates
but also in its effects on the fraction of testosterone and
oestradiol which circulates in the protein-free, biologically
active form. It is well known that a reduction in SHBG
levels leads to an increase in % free testosterone and
oestradiol (Anderson, 1974). When the mean levels of SHBG
found in this study are entered into our previously
determined equation relating SHBG to % free oestradiol
(Dowsett et al., 1984b), the proportion of oestradiol which is
protein-free can be predicted to have increased by approxi-
mately 40% in the low-dose group and approximately 50%
in the high-dose group after at least 3 months' treatment.
It is therefore likely that although the reduction in total
oestradiol levels approaches that which we have observed in
patients treated with the aromatase inhibitors aminoglute-
thimide (Dowsett et al., 1985b) and 4 hydroxyandrostenedione
(Dowsett et al., submitted), i.e. to between 40 and 50% of
pretreatment levels, the fall in the biologically active free
fraction, is probably only to about 70-80% of pretreatment
levels. This is in closer agreement with the fall in total
oestrone levels (whose free fraction is not modified signifi-
cantly by changes in SHBG) and is similar to that which
we observed for both oestrone and oestradiol in patients
during adrenal suppression with 20mg hydrocortisone twice
daily (Harris et al., 1984). The effects on metabolic clearanceEFFECTS OF MPA ON SHBG AND SEX STEROIDS 313
rate and biological activity make it important to measure
SHBG levels in studies of the endocrine effects of any
new agent, and when SHBG levels are shown to be affected
it is essential that these changes are considered in the
interpretation of changes in oestrogen and androgen levels.
In conclusion it appears that MPA does suppress the
synthesis of postmenopausal oestrogen levels by a reduction
in adrenal steroidogenesis, which may be more marked with
the higher dose. However, since the degree of suppression is
similar to that achieved with 40mg hydrocrotisone daily,
which is of relatively low efficacy in breast cancer (Santen,
1982), it is likely that this effect plays a relatively minor part
in the overall activity of MPA. The clinical effects of MPA
are probably more dependent on its direct action on receptor
levels and enzyme activity within the tumour.
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